Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Akero Therapeutics

Rank#3282

Market Cap4.50B

CountryUnited States

Summary

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

History

Akeron Therapeutics was founded in 2016 by a group of scientists, entrepreneurs and physicians dedicated to finding better treatments for people with serious and life-threatening diseases. Since then, we have relentlessly pursued our mission of driving transformative therapeutic advances for patients with complex diseases and disorders.

Mission

Our mission is to accelerate the discovery, development and delivery of breakthrough therapies to address unmet medical needs. We pursue innovation and collaboration to develop transformative treatments in areas with significant unmet need.

Vision

Our vision is to be a leader in the development of cutting-edge therapies that offer transformative potential for patients with life-threatening and chronic diseases.

References

https://in.investing.com/equities/akero-therapeutics-inc

https://finance.yahoo.com/quote/AKRO/profile?p=AKRO

https://www.comparably.com/companies/abcro/mission

https://www.crunchbase.com/organization/akero-therapeutics

https://sec.report/CIK/0001744659

https://companiesmarketcap.com/

https://www.akerotx.com

Leadership team

Dr. Andrew Cheng M.D., Ph.D. (Pres, CEO & Director)

Dr. Jonathan M. Young J.D., Ph.D. (Co-Founder, Exec. VP, COO & Sec.)

Dr. Timothy Rolph (Co-Founder & Chief Scientific Officer)

Products / Services

Biotechnology, Life Science, Therapeutics

Address

Cambridge, Massachusetts, United States

Established

2017-01-01

Company Registration

SEC CIK number: 0001744659

Traded as

AKRO

Website

https://www.akerotx.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Akero Therapeutics

Rank#3282

Market Cap4.50B

CountryUnited States

Summary

History

Mission

Vision

Our vision is to be a leader in the development of cutting-edge therapies that offer transformative potential for patients with life-threatening and chronic diseases.

References

https://in.investing.com/equities/akero-therapeutics-inc

https://finance.yahoo.com/quote/AKRO/profile?p=AKRO

https://www.comparably.com/companies/abcro/mission

https://www.crunchbase.com/organization/akero-therapeutics

https://sec.report/CIK/0001744659

https://companiesmarketcap.com/

https://www.akerotx.com

Leadership team

Dr. Andrew Cheng M.D., Ph.D. (Pres, CEO & Director)

Dr. Jonathan M. Young J.D., Ph.D. (Co-Founder, Exec. VP, COO & Sec.)

Dr. Timothy Rolph (Co-Founder & Chief Scientific Officer)